Your browser is no longer supported. Please, upgrade your browser.
Atara Biotherapeutics, Inc.
Index- P/E- EPS (ttm)-3.86 Insider Own1.20% Shs Outstand91.46M Perf Week-5.77%
Market Cap1.06B Forward P/E- EPS next Y-3.43 Insider Trans-5.44% Shs Float81.54M Perf Month-3.85%
Income-311.40M PEG- EPS next Q-0.90 Inst Own- Short Float15.33% Perf Quarter-36.10%
Sales3.60M P/S293.27 EPS this Y26.90% Inst Trans0.27% Short Ratio13.47 Perf Half Y-4.61%
Book/sh4.36 P/B3.04 EPS next Y4.70% ROA-63.80% Target Price- Perf Year30.57%
Cash/sh5.46 P/C2.43 EPS next 5Y- ROE-78.00% 52W Range8.90 - 28.20 Perf YTD-32.55%
Dividend- P/FCF- EPS past 5Y-13.10% ROI- 52W High-53.05% Beta2.40
Dividend %- Quick Ratio5.50 Sales past 5Y- Gross Margin- 52W Low48.76% ATR0.68
Employees480 Current Ratio5.50 Sales Q/Q- Oper. Margin- RSI (14)40.01 Volatility5.95% 4.80%
OptionableYes Debt/Eq0.00 EPS Q/Q28.70% Profit Margin- Rel Volume0.56 Prev Close13.59
ShortableYes LT Debt/Eq0.00 EarningsMay 04 AMC Payout- Avg Volume927.89K Price13.24
Recom1.90 SMA20-4.44% SMA50-10.77% SMA200-19.25% Volume524,314 Change-2.58%
Dec-09-20Downgrade Citigroup Buy → Neutral $20 → $27
Dec-08-20Reiterated H.C. Wainwright Buy $28 → $31
Nov-10-20Reiterated H.C. Wainwright Buy $26 → $28
Jun-30-20Initiated Evercore ISI Outperform
Jun-15-20Initiated H.C. Wainwright Buy $25
Apr-23-20Upgrade Citigroup Neutral → Buy $14
Nov-08-19Downgrade JP Morgan Overweight → Neutral $43 → $22
Sep-27-19Downgrade Goldman Neutral → Sell $14 → $9
Sep-16-19Downgrade Jefferies Buy → Hold $32 → $15
Jun-04-19Upgrade Citigroup Sell → Neutral $23 → $24
May-30-19Initiated ROTH Capital Buy
May-23-19Initiated Stifel Buy
Jan-23-19Initiated Mizuho Buy
Apr-10-18Initiated JP Morgan Overweight $56
Mar-16-18Initiated Guggenheim Neutral
Mar-05-18Reiterated Jefferies Buy $30 → $46
Feb-28-18Downgrade JMP Securities Mkt Outperform → Mkt Perform
Feb-15-18Downgrade Citigroup Neutral → Sell
Jan-03-18Upgrade Citigroup Sell → Neutral
Oct-06-17Resumed Goldman Neutral
May-10-21 08:30AM  
May-07-21 04:01PM  
May-04-21 05:20PM  
Apr-27-21 05:51PM  
Apr-26-21 01:17AM  
Apr-02-21 04:35PM  
Mar-21-21 03:58AM  
Mar-14-21 04:00PM  
Mar-09-21 04:01PM  
Mar-05-21 04:01PM  
Mar-02-21 09:30AM  
Mar-01-21 04:05PM  
Feb-18-21 04:01PM  
Feb-08-21 09:00AM  
Jan-19-21 04:14PM  
Jan-10-21 04:06PM  
Jan-06-21 08:30AM  
Jan-04-21 07:30AM  
Dec-08-20 09:26PM  
Dec-07-20 04:07PM  
Dec-06-20 11:00PM  
Nov-16-20 04:01PM  
Nov-15-20 10:00AM  
Nov-13-20 10:31AM  
Nov-12-20 08:30AM  
Nov-10-20 10:30AM  
Nov-09-20 04:01PM  
Nov-08-20 12:47PM  
Nov-02-20 04:01PM  
Oct-06-20 10:08PM  
Sep-22-20 07:11AM  
Sep-16-20 12:19PM  
Sep-14-20 09:28AM  
Sep-13-20 05:15AM  
Sep-11-20 08:00AM  
Sep-09-20 09:36AM  
Sep-08-20 07:00AM  
Sep-01-20 07:00AM  
Aug-12-20 09:53AM  
Aug-05-20 04:01PM  
Aug-04-20 08:19AM  
Jul-29-20 04:01PM  
Jul-21-20 12:00PM  
Jul-01-20 11:28AM  
Jun-30-20 10:19AM  
Jun-24-20 04:34PM  
Jun-23-20 09:48PM  
Jun-17-20 08:47AM  
Jun-15-20 09:57AM  
Jun-05-20 04:15PM  
Jun-04-20 04:01PM  
May-27-20 01:16AM  
May-26-20 04:05PM  
May-19-20 08:30AM  
May-18-20 04:30PM  
May-15-20 09:38AM  
May-14-20 04:05PM  
May-13-20 09:21AM  
May-11-20 04:01PM  
May-08-20 04:12AM  
May-07-20 02:00PM  
May-06-20 04:01PM  
Apr-30-20 04:01PM  
Apr-22-20 08:30PM  
Apr-14-20 04:41PM  
Apr-02-20 08:33AM  
Mar-26-20 10:19AM  
Feb-28-20 07:04AM  
Feb-27-20 07:35AM  
Feb-21-20 04:00PM  
Feb-20-20 04:00PM  
Feb-19-20 04:00PM  
Feb-05-20 08:30AM  
Jan-12-20 02:00PM  
Dec-24-19 10:10AM  
Dec-18-19 07:59AM  
Dec-11-19 11:04PM  
Dec-10-19 12:22PM  
Dec-09-19 10:00AM  
Nov-26-19 04:00PM  
Nov-12-19 09:00AM  
Nov-08-19 05:02AM  
Nov-07-19 07:30AM  
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA2321 for acute myeloid leukemia; and ATA368 for human papillomavirus. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Newell JoeChief Operations OfficerApr 05Sale14.746559,655134,924Apr 07 04:36 PM
Newell JoeChief Operations OfficerMar 26Sale14.582,64038,491135,579Mar 30 05:18 PM
Koppikar UtpalChief Financial OfficerMar 26Sale14.581,76125,675172,582Mar 30 05:19 PM
Newell JoeChief Operations OfficerMar 15Option Exercise12.153,50042,525145,219Mar 15 07:25 PM
Newell JoeChief Operations OfficerMar 15Sale17.417,000121,870138,219Mar 15 07:25 PM
Newell JoeChief Operations OfficerMar 02Sale16.741,66527,872141,719Mar 04 04:08 PM
Touchon PascalPresident and CEOMar 02Sale16.744,88781,808367,621Mar 04 04:06 PM
Koppikar UtpalChief Financial OfficerMar 02Sale16.741,46124,457174,343Mar 04 04:07 PM
Koppikar UtpalChief Financial OfficerFeb 08Sale20.391,75935,866130,546Feb 09 07:59 PM
Newell JoeChief Operations OfficerFeb 08Sale20.393,88679,236105,669Feb 09 07:59 PM
Newell JoeChief Operations OfficerJan 15Option Exercise12.153,50042,525116,555Jan 19 04:02 PM
Newell JoeChief Operations OfficerJan 15Sale18.847,000131,880109,555Jan 19 04:02 PM
Newell JoeChief Operations OfficerDec 16Option Exercise12.153,50042,525120,055Dec 18 06:35 PM
Newell JoeChief Operations OfficerDec 16Sale23.117,000161,735113,055Dec 18 06:35 PM
Newell JoeChief Operations OfficerNov 17Sale19.771,64832,588116,555Nov 18 04:07 PM
Koppikar UtpalChief Financial OfficerNov 17Sale19.771,46929,048132,061Nov 18 04:08 PM
Touchon PascalPresident and CEONov 17Sale19.774,71693,254255,321Nov 18 04:07 PM
Newell JoeChief Operations OfficerNov 13Option Exercise12.153,50042,525125,703Nov 16 04:19 PM
Newell JoeChief Operations OfficerNov 13Sale18.497,500138,688118,203Nov 16 04:19 PM
Touchon PascalPresident and CEOAug 18Sale12.094,80758,117260,037Aug 20 07:39 PM
Koppikar UtpalChief Financial OfficerAug 18Sale12.091,49618,087133,530Aug 20 07:38 PM
Newell JoeChief Operations OfficerAug 18Sale12.091,67820,287122,203Aug 20 07:37 PM
Touchon PascalPresident and CEOJun 25Sale12.9212,135156,784264,844Jun 26 04:18 PM
Koppikar UtpalChief Financial OfficerJun 09Sale10.183,92439,946135,026Jun 10 04:05 PM
Newell JoeChief Operations OfficerMay 18Sale11.221,60317,986123,881May 20 06:11 PM
Koppikar UtpalChief Financial OfficerMay 18Sale11.221,42816,022137,375May 20 06:11 PM
Touchon PascalPresident and CEOMay 18Sale11.223,19535,848276,979May 20 06:10 PM